Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.
Psoriasis is a chronic skin disorder which negatively impacts a patient's quality of life (QoL). A recently published assessment tool, PsoDisk, has been proposed to evaluate patient's QoL. The aim of this study was to test PsoDisk as a QoL assessment tool in psoriatic patients undergoing treatment with adalimumab. A retrospective, monocentric study, including patients who completed at least 48 weeks of both adalimumab therapy and PsoDisk assessment. PASI was assessed by the physician whereas the PsoDisk test was self-performed by the patient. Both were evaluated at each control visit throughout the study-period in order to detect changes in disease severity and the impact of quality of life, respectively. In total, we evaluated 31 patients selected from our database. At baseline, all aspects of patients' psycho-emotional and social lives were impaired. PASI score reduction correlated with a PsoDisk score decrease (r = 0.97; p = 0.02), reflecting an overall improvement of patient's QoL. PsoDisk was found to be easy to administer and intuitive for interpreting clinical results.